IMMP צמיחת רווחי EPS רבעונית Immutep
The quarterly EPS percentage change on GURU.Markets reflects dynamics amid a neutral geopolitical backdrop, with the parameter stabilizing at 3.30. Biotech company Immutep Limited (IMMP) is developing innovative LAG-3 therapy to combat solid tumors. Management is effectively expanding strategic collaboration with global pharma behemoths, confirming the uniqueness of its scientific research.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%9E%D7%95%D7%A0%D7%97%D7%99%D7%9D%20%D7%A9%D7%A0%D7%AA%D7%99%D7%99%D7%9D%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwbxec28.yq-7cu2wow&start=20220704&end=20261111&filename=GURU_Markets_-_IMMP_-_Immutep-Limited_-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "Immutep Ltd (IMMP): צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים מ-04.07.2022 עד 11.11.2026 | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Immutep Corp (IMMP)
For Immutep Limited (IMMP), this indicator serves as a tool to assess the scaling efficiency of its oncology pipeline. The calculation is based on the percentage change in net earnings per share between the current and previous quarters. By analyzing the growth rate of quarterly earnings per share, an investor determines the sustainability of the financial result. For the biotechnology sector, such price action confirms the success of clinical trials. Stable growth indicates the viability of the global expansion strategy.
